肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

EMA确认治疗光化性角化病的Picato凝胶存在致癌风险

2020-04-22 MedSci原创 MedSci原创

皮肤癌光化性角化病Picato(Ingenol Mebutate)凝胶
关注

欧洲药品管理局的安全委员会已确认，治疗皮肤病光化性角化病的Picato (Ingenol Mebutate)凝胶可能会增加患皮肤癌的风险。

欧洲药品管理局的安全委员会（PRAC）已确认，用于治疗皮肤病光化性角化病的Picato(Ingenol Mebutate)凝胶可能会增加患皮肤癌的风险。

在对所有可用数据进行安全审查之后，该机构得出结论，该药物的风险大于其益处。

将Picato与另一种用于治疗光化性角化病的药物imiquimod进行了比较，结果显示在用Picato治疗的皮肤区域，皮肤癌（尤其是鳞状细胞癌）的发生率更高。

欧盟已撤销Picato的销售许可，并提醒接受过该药物治疗的患者发现皮肤异常变化或生长的情况，需要及时寻求医疗咨询。

光化性角化病是日光长期照射或电离辐射刺激引致的表皮角化过度疾病，也称为日光性角化病或老年性角化病，是最常见的一种上皮性癌前期损害。

原始出处：

http://www.pharmatimes.com/news/ema_confirms_skin_cancer_risk_with_leos_picato_1338594

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2021-03-02 jinweidong

    #光化性角化病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2021-02-19 lq1767

    #致癌风险#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2021-03-20 docwu2019

    #癌风险#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-24 fengyi812

    #EMA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-24 jambiya

    #致癌#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-24 lishizhe

    #凝胶#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-24 guihongzh

    #角化病#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1648840, encodeId=290716488401d, content=<a href='/topic/show?id=d7a328e40fd' target=_blank style='color:#2F92EE;'>#光化性角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28740, encryptionId=d7a328e40fd, topicName=光化性角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a8a23689373, createdName=jinweidong, createdTime=Tue Mar 02 14:13:17 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023318, encodeId=649b20233182b, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 19 06:13:17 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061931, encodeId=15aa20619312a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Mar 20 18:13:17 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371002, encodeId=deb613e100240, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461056, encodeId=58f414610567d, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623597, encodeId=2a2b162359e83, content=<a href='/topic/show?id=a323909163b' target=_blank style='color:#2F92EE;'>#角化病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90916, encryptionId=a323909163b, topicName=角化病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10a720562694, createdName=guihongzh, createdTime=Fri Apr 24 02:13:17 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382071, encodeId=a0353820e187, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Wed Apr 22 18:09:27 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-22 946207329

    感谢分享

    0

相关资讯

BMJ：APP用于疑似皮肤癌患者的识别效果研究

研究认为，现阶段APP用于可疑皮肤癌病变的识别能力较差

Nature：HPV免疫应答可抵御皮肤癌

免疫应答遭到抑制，很有可能增加罹患病毒感染相关的肿瘤的概率。有报道指出，皮肤鳞状细胞癌（squamous cell carcinoma，简称SCC）与beta型人类乳头瘤病毒（beta human papillomavirus，简称β-HPV）相关，而免疫应答受到抑制的病人，罹患此种肿瘤的概率是健康人群的一百倍以上。但是，学界对于皮肤癌与HPV之间的因果关系并没有给出明确的答案。

PNAS：预测皮肤癌风险新方法！依赖于紫外线敏感的“超热点”

紫外线辐射是造成皮肤癌的主要原因，筛选超热点将使测量一个人过去的紫外线暴露更加容易，可能会提供一种预测人的皮肤癌风险的新方法。

Nat Commun：部分皮肤癌可能起源于毛囊

一项新的研究发现，一些致命的皮肤癌可能是由毛囊干细胞，而非皮肤细胞恶化产生的。

PNAS：科学家鉴别出能有效预测皮肤癌风险的“超级热点区域”

最近，一项刊登在国际杂志Proceedings of the National Academy of Sciences上的研究报告中，来自耶鲁大学的科学家们通过研究在人类基因中发现了“超级热点区域”（hyperhotspots），相比基因组平均水平而言，这些位点对来自太阳光紫外线辐射的敏感程度是前者的170倍。暴露于紫外线辐射中往往是引发皮肤癌的主要原因，而对这些超级热点区域进行筛选或许能帮助有效

Lancet Oncol：Cemiplimab治疗局部晚期皮肤鳞状细胞癌

研究认为，Cemiplimab在局部晚期皮肤鳞状细胞癌患者中显示了良好的抗肿瘤活性和可接受的安全性